Longevity Health Holdings, Inc. is a regenerative medicine biotech company, which focuses on leveraging its core platform technology plasma based bioactive material to stimulate tissue repair or growth after severe injury, disease or aging. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 15 full-time employees. The company went IPO on 2021-07-29. The firm has two cosmetic product lines, Carmell Secretomeand and Elevai Exosomes, that support skin and hair health. All of its cosmetic skincare and haircare products are tailored to meet the demanding technical requirements of professional care providers and discerning retail consumers. The Carmell Secretome consists of a potent cocktail of growth factors, proteins, and peptides extracted from allogeneic human platelets. The Carmell Secretome product portfolio and pipeline includes Face and Neck Collection (Retail), ProSynergy Collection (Doctors/Medspas), and others. The Elevai Exosomes are nano-sized extracellular vesicles containing growth factors, cytokines, peptides, and other small molecules involved in the body’s natural healing process. The Elevai Exosomes skincare products include Elevai Empower and Elevai Enfinity.
根据最新的财务报表(Form-10K),Longevity Health Holdings Inc 的总资产为 $0,净亏损为 $0
XAGE 的关键财务比率是什么?
Longevity Health Holdings Inc 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Longevity Health Holdings Inc 的收入按细分市场或地理位置如何划分?
Longevity Health Holdings Inc 最大收入来源是 Life and Health Insurance,在最近的收益报告中收入为 146,867,836。就地区而言, China 是 Longevity Health Holdings Inc 的主要市场,收入为 140,220,314。
Longevity Health Holdings Inc 是否盈利?
否,根据最新的财务报表,Longevity Health Holdings Inc 的净亏损为 $0